Panel Discussion: Assessing the Risk of Insertional Mutagenesis by AAV Gene Therapies
Time: 5:45 pm
day: Day One
This panel will be a structured conversation designed to answer key questions such as:
- What is the rate of integration of AAV vectors?
- What is the structure of the integrated viral sequences?
- Is the risk dependent on dose?
- What is the role of species differences when looking at preclinical data, will this translate to humans?
- The need for industry collaboration to share data around risk of mutagenesis